
Supplementary Material

Novel Cinnamaldehyde Hydrazones: Design, In Silico Evaluation, Synthesis, and Cytotoxic Activity

Boryana Nikolova-Mladenova [1,*], Rositsa Mihaylova [2], Mariyana Atanasova [1,3,*]

[1] Department of Chemistry, Faculty of Pharmacy, Medical University of Sofia, 2 Dunav Str., 1000 Sofia, Bulgaria
[2] Department of Pharmacology, Pharmacotherapy and Toxicology, Faculty of Pharmacy, Medical University of Sofia, 2 Dunav Str., 1000 Sofia, Bulgaria; rmihaylova@pharmfac.mu-sofia.bg
[3] Centre of Excellence in Informatics and Information and Communication Technologies, 1113 Sofia, Bulgaria
[*] Correspondence: borianank@pharmfac.mu-sofia.bg; matanasova@pharmfac.mu-sofia.bg

Compound CA1



N'-((1*E*,2*E*)-3-phenylallylidene)benzohydrazide




Figure S1. HR ESI–MS spectra of the compound **CA1**.




Figure S2. IR spectra of the compound **CA1**.




Figure S3. ^{1}H NMR spectra of the compound **CA1**.





Figure S4. ^{13}C NMR spectra of the compound **CA1**.

Compound CA2



4-methyl-*N*'-((1*E*,2*E*)-3-phenylallylidene)benzohydrazide




Figure S5. HR ESI–MS spectra of the compound **CA2**.




Figure S6. IR spectra of the compound **CA2**.




Figure S7. ^{1}H NMR spectra of the compound **CA2**.





Figure S8. ^{13}C NMR spectra of the compound **CA2**.

Compound CA3



4-chloro-*N*'-((1*E*,2*E*)-3-phenylallylidene)benzohydrazide




Figure S9. HR ESI–MS spectra of the compound **CA3**.




Figure S10. IR spectra of the compound **CA3**.




Figure S11. ^{1}H NMR spectra of the compound **CA3**.





Figure S12. ^{13}C NMR spectra of the compound **CA3**.

Compound CA4



N'-((1*E*,2*E*)-3-phenylallylidene)isonicotinohydrazide




Figure S13. HR ESI–MS spectra of the compound **CA4**.




Figure S14. IR spectra of the compound **CA4**.




Figure S15. ^{1}H NMR spectra of the compound **CA4**.





Figure S16. ^{13}C NMR spectra of the compound **CA4**.

Compound CA5



4-hydroxy-*N*'-((1*E*,2*E*)-3-phenylallylidene)benzohydrazide




Figure S17. HR ESI–MS spectra of the compound **CA5**.




Figure S18. IR spectra of the compound **CA5**.




Figure S19. ^{1}H NMR spectra of the compound **CA5**.





Figure S20. ^{13}C NMR spectra of the compound **CA5**.

Compound CA6



4-methoxy-*N*'-((1*E*,2*E*)-3-phenylallylidene)benzohydrazide




Figure S21. HR ESI–MS spectra of the compound **CA6**.




Figure S22. IR spectra of the compound **CA6**.




Figure S23. ^{1}H NMR spectra of the compound **CA6**.





Figure S24. ^{13}C NMR spectra of the compound **CA6**.

Compound CA7



4-nitro-*N*'-((1*E*,2*E*)-3-phenylallylidene)benzohydrazide




Figure S25. HR ESI–MS spectra of the compound **CA7**.




Figure S26. IR spectra of the compound **CA7**.




Figure S27. ^{1}H NMR spectra of the compound **CA7**.





Figure S28. ^{13}C NMR spectra of the compound **CA7**.

Compound CA8



4-amino-*N*'-((1*E*,2*E*)-3-phenylallylidene)benzohydrazide




Figure S29. HR ESI–MS spectra of the compound **CA8**.




Figure S30. IR spectra of the compound **CA8**.




Figure S31. ^{1}H NMR spectra of the compound **CA8**.




Figure S32. ^{13}C NMR spectra of the compound **CA8**.